Pathophysiological links between obstructive sleep apnea syndrome and metabolic syndrome;Legami fisiopatologici tra sindrome delle apnee ostruttive notturne e sindrome metabolica

Giornale Italiano di Cardiologia

Volumn 11, Issue 6, 2010, Pages 453-459

  Mugnai, Giacomo ^a  

^a UNIVERSITY HOSPITAL OF VERONA   (Italy)

Author keywords

Metabolic syndrome; Obstructive sleep apnea

Indexed keywords

CARDIOVASCULAR RISK; DISEASE ASSOCIATION; HUMAN; HYPOXIA; INFLAMMATION; INSULIN SENSITIVITY; METABOLIC SYNDROME X; OXIDATIVE STRESS; POSITIVE END EXPIRATORY PRESSURE; REVIEW; RISK FACTOR; RISK REDUCTION; SLEEP APNEA SYNDROME; TREATMENT OUTCOME; AGE; AGED; BLOOD; CARDIOVASCULAR DISEASES; CLINICAL TRIAL (TOPIC); COMPARATIVE STUDY; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE TEST; HYPERTENSION; INSULIN RESISTANCE; MEDLINE; METABOLISM; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PATHOPHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL (TOPIC); SLEEP APNEA, OBSTRUCTIVE; STROKE; SUDDEN CARDIAC DEATH;

GLUCOSE BLOOD LEVEL; LEPTIN;

AGE FACTORS; AGED; BLOOD GLUCOSE; CARDIOVASCULAR DISEASES; CLINICAL TRIALS AS TOPIC; CONTINUOUS POSITIVE AIRWAY PRESSURE; DEATH, SUDDEN, CARDIAC; DIABETES MELLITUS, TYPE 2; GLUCOSE TOLERANCE TEST; HUMANS; HYPERTENSION; INSULIN RESISTANCE; LEPTIN; MEDLINE; METABOLIC SYNDROME X; OBESITY; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS; SLEEP APNEA, OBSTRUCTIVE; STROKE;

EID: 77954506450     PISSN: 18276806     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (49)

1. Young T, Peppard PE, Gottlieb DJ. Epidemiology of obstructive sleep apnea: a population health perspective. Am J Respir Crit Care Med 2002; 165: 1217-39. (Pubitemid 34461732)
2. Coughlin SR, Mawdsley L, Mugarza JA, Calverley PM, Wilding JP. Obstructive sleep apnoea is independently associated with an increased prevalence of metabolic syndrome. Eur Heart J 2004; 25: 735-41.
3. Wilcox I, McNamara SG, Collins FL, Grunstein RR, Sullivan CE. "Syndrome Z": the interaction of sleep apnoea, vascular risk factors and heart disease. Thorax 1998; 53 (Suppl 3): S25-S28.
4. Idris I, Hall AP, O'Reilly J, et al. Obstructive sleep apnoea in patients with type 2 diabetes: aetiology and implications for clinical care. Diabetes Obes Metab 2009; 11: 733-41.
5. Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet 2005; 365: 1415-28.
6. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001; 285: 2486-97.
7. Alberti KG, Zimmet P, Shaw J; IDF Epidemiology Task Force Consensus Group. The metabolic syndrome - a new worldwide definition. Lancet 2005; 366: 1059-62.
8. Magi L, Stramenga C, Morosini P; Gruppo di Studio SIMAP. Prevalence of the metabolic syndrome among Italian adults. Findings from the SIMAP study. Recenti Prog Med 2005; 96: 280-3.
9. Zuliani G, Volpato S, Galvani M, et al. Elevated C-reactive protein levels and metabolic syndrome in the elderly: the role of central obesity data from the InChianti study. Atherosclerosis 2009; 203: 626-32.
10. Marin JM, Carrizo SJ, Vicente E, Agusti AG. Long-term cardiovascular outcomes in men with obstructive sleep apnoea-hypopnoea with or without treatment with continuous positive airway pressure: an observational study. Lancet 2005; 365: 1046-53.
11. Gruber A, Horwood F, Sithole J, Ali NJ, Idris I. Obstructive sleep apnoea is independently associated with the metabolic syndrome but not insulin resistance state. Cardiovasc Diabetol 2006; 5: 22.
12. Makino S, Handa H, Suzukawa K, et al. Obstructive sleep apnoea syndrome, plasma adiponectin levels, and insulin resistance. Clin Endocrinol (Oxf) 2006; 64: 12-9.
13. Vgontzas AN, Papanicolaou DA, Bixler EO, et al. Sleep apnea and daytime sleepiness and fatigue: relation to visceral obesity, insulin resistance, and hypercytokinemia. J Clin Endocrinol Metab 2000; 85: 1151-8.
14. Larsen JJ, Hansen JM, Olsen NV, Galbo H, Dela F. The effect of altitude hypoxia on glucose homeostasis in men. J Physiol 1997; 504 (Pt 1): 241-9.
15. Reaven G. Metabolic syndrome: pathophysiology and implications for management of cardiovascular disease. Circulation 2002; 106: 286-8. (Pubitemid 34778947)
16. Iiyori N, Alonso LC, Li J, et al. Intermittent hypoxia causes insulin resistance in lean mice independent of autonomic activity. Am J Respir Crit Care Med 2007; 175: 851-7.
17. Spiegel K, Leproult R, Van Cauter E. Impact of sleep debt on metabolic and endocrine function. Lancet 1999; 354: 1435-9.
18. Wolk R, Somers VK. Sleep and the metabolic syndrome. Exp Physiol 2007; 92: 67-78.
19. Tasali E, Ip MS. Obstructive sleep apnea and metabolic syndrome: alterations in glucose metabolism and inflammation. Proc Am Thorac Soc 2008; 5: 207-17.
20. Ridker PM, Cook N. Clinical usefulness of very high and very low levels of C-reactive protein across the full range of Framingham risk scores. Circulation 2004; 109: 1955-9.
21. Price DT, Loscalzo J. Cellular adhesion molecules and atherogenesis. Am J Med 1999; 107: 85-97. (Pubitemid 29328286)
22. Ryan S, Taylor CT, McNicholas WT. Selective activation of inflammatory pathways by intermittent hypoxia in obstructive sleep apnea syndrome. Circulation 2005; 112: 2660-7.
23. Williams A, Scharf SM. Obstructive sleep apnea, cardiovascular disease, and inflammation: is NF-κB the key? Sleep Breath 2007; 11: 69-76.
24. Jelic S, Padeletti M, Kawut SM, et al. Inflammation, oxidative stress, and repair capacity of the vascular endothelium in obstructive sleep apnea. Circulation 2008; 117: 2270-8.
25. Vita JA, Keaney JF Jr. Endothelial function: a barometer for cardiovascular risk? Circulation 2002; 106: 640-2.
26. Wessendorf TE, Thilmann AF, Wang YM, Schreiber A, Konietzko N, Teschler H. Fibrinogen levels and obstructive sleep apnea in ischemic stroke. Am J Respir Crit Care Med 2000; 162: 2039-42.
27. Von Kanel R, Loredo JS, Ancoli-Israel S, Mills PJ, Dimsdale JE. Elevated plasminogen activator inhibitor 1 in sleep apnea and its relation to the metabolic syndrome: an investigation in 2 different study samples. Metabolism 2007; 56: 969-76.
28. Auwerx J, Staels B. Leptin. Lancet 1998; 351: 737-42.
29. Phillips BG, Kato M, Narkiewicz K, Choe I, Somers VK. Increases in leptin levels, sympathetic drive, and weight gain in obstructive sleep apnea. Am J Physiol Heart Circ Physiol 2000; 279: H234-H237. (Pubitemid 30616665)
30. Galletti F, Barbato A, Versiero M, et al. Circulating leptin levels predict the development of metabolic syndrome in middle-aged men: an 8-year follow-up study. J Hypertens 2007; 25: 1671-7.
31. Peppard PE, Young T, Palta M, Skatrud J. Prospective study of the association between sleep-disordered breathing and hypertension. N Engl J Med 2000; 342: 1378-84. (Pubitemid 30262394)
32. Fletcher EC, Orolinova N, Bader M. Blood pressure response to chronic episodic hypoxia: the renin-angiotensin system. J Appl Physiol 2002; 92: 627-33. (Pubitemid 34671030)
33. Shamsuzzaman AS, Gersh BJ, Somers VK. Obstructive sleep apnea. Implications for cardiac and vascular disease. JAMA 2003; 290: 1906-14.
34. Becker HF, Jerrentrup A, Ploch T, et al. Effect of nasal continuous positive airway pressure treatment on blood pressure in patients with obstructive sleep apnea. Circulation 2003; 107: 68-73. (Pubitemid 36070935)
35. Robinson GV, Smith DM, Langford BA, Davies RJ, Stradling JR. Continuous positive airway pressure does not reduce blood pressure in nonsleepy hypertensive OSA patients. Eur Respir J 2006; 27: 1229-35.
36. Punjabi NM, Shahar E, Redline S, Gottlieb DJ, Givelber R, Resnick HE. Sleep-disordered breathing, glucose intolerance, and insulin resistance: the Sleep Heart Health Study. Am J Epidemiol 2004; 160: 521-30.
37. Peppard PE, Young T, Palta M, Dempsey J, Skatrud J. Longitudinal study of moderate weight change and sleep-disordered breathing. JAMA 2000; 284: 3015-21. (Pubitemid 32014738)
38. Phillips BG, Hisel TM, Kato M, et al. Recent weight gain in patients with newly diagnosed obstructive sleep apnea. J Hypertens 1999; 17: 1297-300.
39. Gianotti L, Pivetti S, Lanfranco F, et al. Concomitant impairment of growth hormone secretion and peripheral sensitivity in obese patients with obstructive sleep apnea syndrome. J Clin Endocrinol Metab 2002; 87: 5052-7.
40. Tan KC, Chow WS, Lam JC, et al. HDL dysfunction in obstructive sleep apnea. Atherosclerosis 2006; 184: 377-82.
41. Harsch IA, Schahin SP, Radespiel-Troger M, et al. Continuous positive airway pressure treatment rapidly improves insulin sensitivity in patients with obstructive sleep apnea syndrome. Am J Respir Crit Care Med 2004; 169: 156-62.
42. Babu AR, Herdegen J, Fogelfeld L, Shott S, Mazzone T. Type 2 diabetes, glycemic control, and continuous positive airway pressure in obstructive sleep apnea. Arch Intern Med 2005; 165: 447-52.
43. Dorkova Z, Petrasova D, Molcanyiova A, Popovnakova M, Tkacova R. Effects of continuous positive airway pressure on cardiovascular risk profile in patients with severe obstructive sleep apnea and metabolic syndrome. Chest 2008; 134: 686-92.
44. West SD, Nicoll DJ, Wallace TM, Matthews DR, Stradling JR. The effect of CPAP on insulin resistance and HbA1c in men with obstructive sleep apnoea and type 2 diabetes. Thorax 2007; 62: 969-74.
45. Coughlin SR, Mawdsley L, Mugarza JA, Wilding JP, Calverley PM. Cardiovascular and metabolic effects of CPAP in obese men with OSA. Eur Respir J 2007; 29: 720-7.
46. Brooks B, Cistulli PA, Borkman M, et al. Obstructive sleep apnea in obese noninsulin-dependent diabetic patients: effect of continuous positive airway pressure treatment on insulin responsiveness. J Clin Endocrinol Metab 1994; 79: 1681-5.
47. Hassaballa HA, Tulaimat A, Herdegen JJ, Mokhlesi B. The effect of continuous positive airway pressure on glucose control in diabetic patients with severe obstructive sleep apnea. Sleep Breath 2005; 9: 176-80. (Pubitemid 44184314)
48. Saarlainen S, Lahtela J, Kallonen E. Effect of nasal CPAP treatment on insulin sensitivity and plasma leptin. J Sleep Res 1997; 6: 146-7. (Pubitemid 27300274)
49. Smurra M, Philip P, Taillard J, Guilleminault C, Bioulac B, Gin H. CPAP treatment does not affect glucose-insulin metabolism in sleep apneic patients. Sleep Med 2001; 2: 207-13.